Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

Détails

ID Serval
serval:BIB_91E1362A1B81
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
Périodique
Inflammatory Bowel Diseases
Auteur(s)
Feagan B.G., Lémann M., Befrits R., Connell W., D'Haens G., Ghosh S., Michetti P., Ochsenkühn T., Panaccione R., Schreiber S., Silverberg M., Sorrentino D., van der Woude C.J., Vermeire S., Rutgeerts P.
ISSN
1536-4844 (Electronic)
ISSN-L
1078-0998
Statut éditorial
Publié
Date de publication
2012
Volume
18
Numéro
1
Pages
152-160
Langue
anglais
Résumé
Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.
Pubmed
Web of science
Création de la notice
09/02/2012 11:29
Dernière modification de la notice
20/08/2019 15:55
Données d'usage